Sugi Predict

Sugi Predict / Compounds / SCHEMBL38017

SCHEMBL38017

SCHEMBL38017

CC(C)(C)OC(=O)N1CC(F)CC1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.42
▸ NR1H2 P55055 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ HTRA1 Q92743 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ DPP4 P27487 2/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ PEPD P12955 1/20 0.33
▸ XPNPEP1 Q9NQW7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811620 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL17760125 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192501 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL2489604 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192921 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1853822 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL641763 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL29038999 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1334717 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL15116701 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232004-A1 FRACTAL FORMULATIONS Nanogyre Sprl (BE) 2023-08-30 — — EP claimed
EP-4463455-B1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SUVEN LIFE SCIENCES LTD (IN) 2026-04-29 — — EP disclosed
US-20250326766-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-10-23 — — US disclosed
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 ZHOU YUHANG (US) 2025-09-11 — — US disclosed
US-12391698-B2 Substituted piperidines and piperazines and methods for the treatment of CNS disorders SUVEN LIFE SCIENCES LIMITED (IN) 2025-08-19 — — US disclosed
EP-4526300-A1 RIPK1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2025-03-26 — — EP disclosed
US-20250092049-A1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SUVEN LIFE SCIENCES LIMITED (IN) 2025-03-20 — — US disclosed
EP-4463455-A1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS Suven Life Sciences Limited (IN) 2024-11-20 — — EP disclosed
EP-4430035-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 Pharma LLC (US) 2024-09-18 — — EP disclosed
EP-3856164-B1 MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS ACHILLION PHARMACEUTICALS INC (US) 2024-08-07 — — EP disclosed
CN-1839120-A Process for producing cis-4-fluoro-L-proline derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2006-09-27 — — CN disclosed
WO-2006089311-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2006-08-24 — — WO disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 — — EP disclosed
EP-1487807-A2 NEW COMPOUNDS Sanofi-Aventis (FR) 2004-12-22 — — EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
WO-2003074500-A2 N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS SANOFI-AVENTIS (FR) 2003-09-12 — — WO disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 HSD17B10 3461/4885NR1H2 2538/4885CHRM2 2236/4885
US-12391698-B2 Substituted piperidines and piperazines and methods for the treatment of CNS disorders GRIN2C, SLC1A2, CNR2 HSD17B10 2416/4885NR1H2 832/4885CHRM2 508/4885
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 PF4, F12, F2 HSD17B10 1989/4885NR1H2 2055/4885CHRM2 1605/4885
US-20250092049-A1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS GRIN2C, CNR2, INA HSD17B10 593/4885NR1H2 561/4885CHRM2 618/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 HSD17B10 3504/4885NR1H2 2668/4885CHRM2 2195/4885
US-20250326766-A1 RIPK1 INHIBITORS AND METHODS OF USE RIPK1, RIPK2, RIPK3 HSD17B10 3015/4885NR1H2 1232/4885CHRM2 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.